SearchDictionaryMobileLogin

Ronald N Jones Selected Research

Respiratory Tract Infections (Respiratory Tract Infection)

06/2008Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.
05/2007Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
02/2007Cefdinir: an oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections.
07/2005Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
04/2003Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
09/2002Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
09/2002Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
05/2002Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.

Articles by Research Topic

Disease

12Infection
05/2008 - 03/2002
8Respiratory Tract Infections (Respiratory Tract Infection)
06/2008 - 05/2002
6Pneumonia (Pneumonitis)
05/2007 - 09/2002
5Soft Tissue Infections
05/2007 - 08/2002
3Maxillary Sinusitis
05/2008 - 06/2004
1Urinary Tract Infections (Urinary Tract Infection)
01/2005
1Community-Acquired Infections
12/2004

Drug/Important Bio-Agent (IBA)

6tigecycline (Tygacil)FDA Link
12/2007 - 07/2004
6garenoxacinIBA
05/2007 - 05/2002
5gatifloxacin (Zymar)FDA Link
06/2004 - 09/2002
4cefdinir (CFDN)FDA LinkGeneric
02/2007 - 08/2004
3Ofloxacin (Levofloxacin)FDA LinkGeneric
05/2008 - 06/2005
2omiganan pentahydrochlorideIBA
05/2008 - 03/2008
2beta-LactamsIBA
03/2007 - 06/2005
1cefditorenIBA
06/2008
1Cephalosporins (Cephalosporin Antibiotics)IBA
08/2006
1NVP PDF 713IBA
05/2006
1peptide deformylaseIBA
05/2006
1dalbavancinIBA
02/2006
1Doxycycline (Vibramycin)FDA LinkGeneric
06/2004
1FluoroquinolonesIBA
09/2002
1tazobactamIBA
05/2002
1PiperacillinFDA Link
05/2002
1cefepime (Maxipime)FDA LinkGeneric
03/2002